ClinicalTrials.gov
ClinicalTrials.gov Menu

Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours (TOTEM2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00918320
Recruitment Status : Completed
First Posted : June 11, 2009
Last Update Posted : January 26, 2016
Sponsor:
Collaborators:
St. Anna Kinderkrebsforschung
Catholic University of the Sacred Heart
Erasmus Medical Center
Information provided by (Responsible Party):
Gustave Roussy, Cancer Campus, Grand Paris

June 8, 2009
June 11, 2009
January 26, 2016
June 2009
October 2013   (Final data collection date for primary outcome measure)
Response rate [ Time Frame: after 2 cycles=8 weeks of therapy ]
Same as current
Complete list of historical versions of study NCT00918320 on ClinicalTrials.gov Archive Site
  • safety and adverse event profile of the combination safety and adverse event [ Time Frame: 28 days ]
  • time-to-event endpoints: duration of response, time to progressive disease, time to treatment failure and overall survival [ Time Frame: every 8 weeks ]
Same as current
Not Provided
Not Provided
 
Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours
Phase 2 Single- Arm Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Neuroblastoma and Other Paediatric Solid Tumours
The purpose of the study is to determine whether the combination of Hycamtin (Topotecan) and Temozolomide is effective in the treatment of relapsed and refractory neuroblastoma and other paediatric solid tumors.

Current treatments for malignant paediatric solid tumors involve a combination of chemotherapy, surgery and, in certain cases, radiotherapy. This multidisciplinary approach leads to an overall cure of approximately 70%. Nevertheless, cancer mortality remains the leading cause of disease-related death in children and adolescents between 1 and 19 years. This is due to diseases with a poor prognosis, such as metastatic neuroblastoma, sarcoma in soft tissue and bone and brain tumors. New effective treatments must be found in order to continue to increase the cure rate of children and adolescents treated for cancer, as well as to improve the cured patients' quality of life

Neuroblastoma (NB) is a malignant paediatric tumour derived from primordial neural crest cells. This tumor accounts for 8% to 10% of all cancers with a median age of onset of 22 months. The primary tumor may be located in different anatomic sites such as abdomen (65%), thorax (19%), pelvis (2%), and cervix (1%). The strongest prognostic factors are age and stage. Localized NB and those occuring in infants have a 90% survival rate when the biological profile is favorable. Conversely, in case of Myc-N amplification, survival is around 30% after conventional treatment and 70% after intensification. More than 50% of patients have a disseminated tumor at diagnosis, and Stage 4 neuroblastoma in patients older than 1 year of age represents the most frequent form. Neuroblastoma is a chemosensitive tumor. Chemotherapy is indicated in large primary tumours to reduce the volume and attempt a safe surgical resection and to eradicate tumour metastases in disseminated NB. The most frequently used drugs are alkylating and platinum agents (cyclophosphamide, melphalan, cisplatin, carboplatin), topoisomerase II inhibitors (doxorubicin, etoposide) and vinca-alkaloids (vincristine). High-dose chemotherapy (busulfan, melphalan, carboplatin, etoposide) with autologous bone marrow stem cell support is used as a consolidation treatment in patients with metastatic disease, as well as maintenance therapy with retinoid acid. Although such an intensive strategy, the probability of survival of patients over 1 year of age with Stage 4 neuroblastoma is less than 40%. New drugs are urgently needed for patients with recurrent neuroblastoma.

Central nervous system (CNS) tumors as an entity represent the second most frequent malignancy in childhood and adolescents. The incidence rate of childhood primary benign and malignant brain tumors is 3.9 cases per 100,000 person-years, and appears to be increasing. Two thirds of the new cases are in children less than 15 years of age. The morbidity associated with CNS tumors exceeds those of other malignancies and is undoubtedly a result of the neurological and cognitive deficits associated with both the tumor itself and aggressive multimodal therapy. Current treatment involves surgical resection, mostly combined with irradiation and/or chemotherapy. This multidisciplinary approach leads to a cure in about 55% of all brain tumour patients. However, the outcome in small children and certain malignancies, such as high grade astrocytomas, brain stem glioma and atypical teratoid/rhabdoid tumors and metastatic primary neuroectodermal tumors (PNET)/medulloblastoma is still dismal. In addition, treatment with irradiation and/or the combination of different chemotherapeutic agents is at the limit of tolerance inducing renal, hepatic, auditory, or hematological toxicity. Moreover, irradiation to the cerebral hemispheres, especially in small children, induces devastating sequelae. Clinical resistance to anticancer agents is the primary reason for treatment failure in childhood cancer and the development of new agents with a new profile of anti-tumour activity and toxicity is highly warranted.

Other relapsed/refractory non-CNS solid tumors include nephroblastoma, osteosarcoma, Ewing's sarcoma, rhabdomyosarcoma and soft-tissue sarcomas, and rarer tumours, such as hepatoblastoma, retinoblastoma, nasopharyngeal carcinoma, and germ-cell tumours. For most of these tumors, treatment protocols are available for first-line therapy; to a lesser extent, treatment recommendations are proposed in case of relapse. Depending on the disease, type, and localization of relapse, treatment may include combinations of salvage chemotherapy, including high-dose chemotherapy with stem cell rescue, radiotherapy, and surgery.

In several of these diseases, temozolomide (as well as topoisomerase I inhibitors, such as irinotecan and Topotecan) have shown single agent activity and may be used in combination schedules.

Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Neuroblastoma
  • Brain Tumors
  • Solid Tumors
Drug: Temozolomide/Hycamtin (Topotecan)

Temozolomide: bottles containing 5 capsules of 5, 20, 100 and 250 mg

Hycamtin (Topotecan): a lyophilisate for infusion in vials containing 4 mg

Patients receive during 5 days (Day 1 to Day 5):

Temozolomide 150 mg/m2/day per os, dose will be adjusted to the closest 5 mg, followed one hour later by Hycamtin(Topotecan) 0.75 mg/m2/day as an intravenous infusion over 30 minutes

Other Name: Hycamtin:Topotecan
Experimental: Toptecan + temozolomide
Intervention: Drug: Temozolomide/Hycamtin (Topotecan)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
129
93
August 2015
October 2013   (Final data collection date for primary outcome measure)

Inclusion criteria:

  • Histologically or cytologically confirmed neuroblastoma, brain tumor or other solid tumor (at diagnosis)
  • Relapsed or refractory tumors in which correct standard treatment approaches have failed
  • No more than 2 lines of prior chemotherapy
  • Measurable primary and/or metastatic disease on CT/MRI at least one bi-dimensionally measurable lesion.

For patients with neuroblastoma, measurable disease will be defined by the modified International Neuroblastoma Staging System (Brodeur et al.1993) completed with MIBG scoring.

  • Age at inclusion: 6 months to ≤ 20 years
  • Lansky play score ≥ 70% or ECOG performance status ≤ 1
  • Life expectancy ≥ 3 months
  • Adequate organ function:

Adequate haematological function: haemoglobin ≥ 80 g/l, neutrophil count ≥ 1.0 x 109/L, platelet count ≥ 100 x 109/L; in case of bone marrow disease: neutrophils ≥ 0.5 x 109/l and platelets ≥ 75 x 109/l;

Adequate renal function: normal creatinine related to patient's age:

  • 0 - 1 year: ≤ 40 µmol/L
  • 1 - 15 years: ≤ 65 µmol/L
  • 15 - 20 years: ≤ 110 µmol/L Adequate hepatic function: bilirubin ≤ 1.5 x ULN; AST and ALT ≤ 2.5 x ULN (AST, ALT ≤5xULN in case of liver metastases)

    • Wash-out of 4 weeks in case of prior chemotherapy, 6 weeks if treatment included nitrosoureas, 2 weeks in case of vincristine alone; 6 weeks in case of prior radiotherapy (except palliative radiotherapy on non measurable lesions). Patients must have recovered from the acute toxic effects of all prior therapy before enrolment into the study.
    • Patients previously treated with only one of the 2 drugs are eligible.
    • Able to comply with scheduled follow-up and with management of toxicity.
    • All patients with reproductive potential must practice an effective method of birth control while on study. Female patients aged > 12 years must have a negative pregnancy test within 7 days before study treatment.
    • Written informed consent from patient, parents or legal guardian.

Exclusion Criteria:

  • Concurrent administration of any other anti-tumour therapy.
  • Serious concomitant systemic disorder (for example, active infection including HIV or cardiac disease) that in the opinion of the investigator, would compromise the patient's ability to complete the study.
  • History of allergic reaction to the compounds or their solvents.
  • History of allergic reaction to Dacarbazine (DITC).
  • Galactosemia, Glucose-galactose malabsorption or lactase deficiency.
  • Pregnant or breast feeding young women.
  • Presence of symptomatic brain metastases in patients with solid non-CNS tumors.
Sexes Eligible for Study: All
6 Months to 20 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT00918320
CSET 2008/1378
Yes
Not Provided
Not Provided
Gustave Roussy, Cancer Campus, Grand Paris
Gustave Roussy, Cancer Campus, Grand Paris
  • St. Anna Kinderkrebsforschung
  • Catholic University of the Sacred Heart
  • Erasmus Medical Center
Principal Investigator: Birgit Geoerger, MD, PHD Gustave Roussy, Cancer Campus, Grand Paris
Gustave Roussy, Cancer Campus, Grand Paris
January 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP